Literature DB >> 16704439

C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders.

Jonathan S C Caudill1, Alexander J Sternberg, Chin-Yang Li, Ayalew Tefferi, Terra L Lasho, David P Steensma.   

Abstract

C-terminal somatic mutations in nucleophosmin (NPM), a nucleolar shuttling protein that binds p53 and p19(Arf), were recently described in karyotypically normal acute myeloid leukaemia (AML). We analysed primary marrow samples from 150 patients with various chronic myeloid disorders for mutations in the NPM1 gene encoding NPM. NPM1 mutations (tetranucleotide duplication) were detected in three patients, all of whom had chronic myelomonocytic leukaemia (CMML) and a short (<1 year) survival, with rapid progression to overt AML. All other patients were NPM1-wild type in the region analysed. In conclusion, C-terminal NPM mutations are uncommon in chronic myeloid neoplasia, but if present may represent an evolving leukaemic clone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16704439     DOI: 10.1111/j.1365-2141.2006.06081.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.

Authors:  Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 2.  Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.

Authors:  Rachel Rau; Patrick Brown
Journal:  Hematol Oncol       Date:  2009-12       Impact factor: 5.271

Review 3.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

4.  Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms.

Authors:  Sanjay S Patel; Caleb Ho; Ryan N Ptashkin; Sam Sadigh; Adam Bagg; Julia T Geyer; Mina L Xu; Thomas Prebet; Emily F Mason; Adam C Seegmiller; Elizabeth A Morgan; David P Steensma; Eric S Winer; Waihay J Wong; Robert P Hasserjian; Olga K Weinberg
Journal:  Blood Adv       Date:  2019-05-14

Review 5.  Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.

Authors:  Jean-Noël Bastie; Romain Aucagne; Nathalie Droin; Eric Solary; Laurent Delva
Journal:  Cell Mol Life Sci       Date:  2012-03-14       Impact factor: 9.261

Review 6.  Biological and clinical consequences of NPM1 mutations in AML.

Authors:  E M Heath; S M Chan; M D Minden; T Murphy; L I Shlush; A D Schimmer
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

Review 7.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

Review 8.  NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors:  Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

9.  Quantitative Assay of Mutated Nucleophosmin in Acute Myeloid Leukemia.

Authors:  Safaa A A Khaled; John Burthem; El-Badry E Abo Elnoor; Lobna F ElToni; Hanan M Ahmed; Sohier M Ahmed
Journal:  J Hematol       Date:  2019-09-30

Review 10.  The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms.

Authors:  Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-01-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.